丁型肝炎病毒与肝脏疾病发病率和死亡率的关联:一项系统文献综述与荟萃分析
该系统综述与荟萃分析纳入12篇文献,评估HBsAg和HDV抗体阳性患者中HDV RNA状态与晚期肝病事件风险的关联。HDV RNA阳性与进展至任何晚期肝病事件的风险比1.48(95%CI 0.93,2.33)及HR 2.62(95%CI 1.55,4.44)相关,且与代偿期肝硬化、失代偿期肝硬化、肝细胞癌、肝移植和肝病相关死亡的更高风险显著相关。作者认为这些发现强调需要改进HDV筛查并衔接治疗以降低肝病发病和死亡风险。
要点
- HDV RNA阳性与任何晚期肝病事件风险比1.48(95%CI 0.93,2.33)及HR 2.62(95%CI 1.55,4.44)相关。
- HDV RNA阳性者进展至代偿期肝硬化风险比1.74(95%CI 1.24,2.45),失代偿期肝硬化HR 3.82(95%CI 1.60,9.10)。
- HDV RNA阳性者肝细胞癌HR 2.97(95%CI 1.87,4.70),肝移植HR 7.07(95%CI 1.61,30.99),肝病相关死亡HR 3.78(95%CI 2.18,6.56)。
核心结论
- HDV RNA阳性患者的肝病进展风险显著高于HDV RNA阴性患者。
- 作者认为这些发现强调需要改进HDV筛查并衔接治疗以降低肝病发病和死亡风险。
研究设计与样本
- 系统文献综述与荟萃分析,共纳入12篇文献。
- 提取HDV RNA阳性/可检测 versus HDV RNA阴性/不可检测患者进展至晚期肝病事件的相对率进行分析。
- 报告的OR和HR及其95%CI采用Hartung-Knapp-Sidik-Jomon方法进行随机效应模型合并。
主要发现
- HDV RNA阳性与任何晚期肝病事件风险升高相关:风险比1.48(95%CI 0.93,2.33);HR 2.62(95%CI 1.55,4.44)。
- 与HDV RNA阴性患者相比,HDV RNA阳性与进展至代偿期肝硬化风险显著更高相关:风险比1.74(95%CI 1.24,2.45)。
- 与HDV RNA阴性患者相比,HDV RNA阳性与进展至失代偿期肝硬化风险显著更高相关:HR 3.82(95%CI 1.60,9.10)。
- 与HDV RNA阴性患者相比,HDV RNA阳性与肝细胞癌风险显著更高相关:HR 2.97(95%CI 1.87,4.70)。
- 与HDV RNA阴性患者相比,HDV RNA阳性与肝移植风险显著更高相关:HR 7.07(95%CI 1.61,30.99);与肝病相关死亡风险显著更高相关:HR 3.78(95%CI 2.18,6.56)。
关键数值与推荐
- HDV RNA阳性 versus HDV RNA阴性:任何晚期肝病事件风险比1.48(95%CI 0.93,2.33),HR 2.62(95%CI 1.55,4.44)。
- HDV RNA阳性 versus HDV RNA阴性:代偿期肝硬化风险比1.74(95%CI 1.24,2.45)。
- HDV RNA阳性 versus HDV RNA阴性:失代偿期肝硬化HR 3.82(95%CI 1.60,9.10)。
- HDV RNA阳性 versus HDV RNA阴性:肝细胞癌HR 2.97(95%CI 1.87,4.70)。
- HDV RNA阳性 versus HDV RNA阴性:肝移植HR 7.07(95%CI 1.61,30.99);肝病相关死亡HR 3.78(95%CI 2.18,6.56)。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Studies have suggested that patients with chronic hepatitis B, either co- or superinfected, have more aggressive liver disease progression than those with the HDV. This systematic literature review and meta-analysis examined whether HDV RNA status is associated with increased risk of advanced liver disease events in patients who are HBsAg and HDV antibody positive. APPROACH AND RESULTS: A total of 12 publications were included. Relative rates of progression to advanced liver disease event for HDV RNA+/detectable versus HDV RNA-/undetectable were extracted for analysis. Reported OR and HRs with 95% CI were pooled using the Hartung-Knapp-Sidik-Jonkman method for random-effects models. The presence of HDV RNA+ was associated with an increased risk of any advanced liver disease event [random effect (95% CI): risk ratio: 1.48 (0.93, 2.33); HR: 2.62 (1.55, 4.44)]. When compared to the patients with HDV RNA- status, HDV RNA+ was associated with a significantly higher risk of progressing to compensated cirrhosis [risk ratio: 1.74 (1.24, 2.45)] decompensated cirrhosis [HR: 3.82 (1.60, 9.10)], HCC [HR: 2.97 (1.87, 4.70)], liver transplantation [HR: 7.07 (1.61, 30.99)], and liver-related mortality [HR: 3.78 (2.18, 6.56)]. CONCLUSIONS: The patients with HDV RNA+ status have a significantly greater risk of liver disease progression than the patients who are HDV RNA-. These findings highlight the need for improved HDV screening and linkage to treatment to reduce the risk of liver-related morbidity and mortality.
引用
- Gish RG, Wong RJ, Di Tanna GL, et al. Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis. Hepatology. 2023. PMID: 37870278. doi:10.1097/HEP.0000000000000642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。